{"id":"disufenton","rwe":[{"pmid":"26771008","year":"2015","title":"Noise-Induced Neural Degeneration and Therapeutic Effect of Antioxidant Drugs.","finding":"","journal":"Journal of audiology & otology","studyType":"Clinical Study"},{"pmid":"18389098","year":"2008","title":"Gateways to clinical trials.","finding":"","journal":"Methods and findings in experimental and clinical pharmacology","studyType":"Clinical Study"},{"pmid":"17922073","year":"2007","title":"Gateways to clinical trials.","finding":"","journal":"Methods and findings in experimental and clinical pharmacology","studyType":"Clinical Study"},{"pmid":"17658905","year":"2007","title":"Neuroprotective effects of free radical scavengers in stroke.","finding":"","journal":"Drugs & aging","studyType":"Clinical Study"},{"pmid":"16801985","year":"2006","title":"Gateways to clinical trials.","finding":"","journal":"Methods and findings in experimental and clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"disufenton","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["disufenton sodium","disufenton"],"offLabel":[],"synonyms":["disufenton sodium","disufenton"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Lipoxygenase","modality":"Small Molecule","drugClass":"disufenton","explanation":"Imagine your body's cells have locks on them, and disufenton is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. This can help control various bodily functions, but without knowing the target, it's hard to say exactly how it works.","oneSentence":"Disufenton works by binding to a specific target, but its exact mechanism of action is unknown.","technicalDetail":"Disufenton is a small molecule that interacts with a specific protein or receptor, but the exact nature of this interaction is unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3162","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DISUFENTON","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DISUFENTON","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:47:44.771818","biosimilars":[],"competitors":[{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"disufenton","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04388475","phase":"PHASE2","title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Oblato, Inc.","startDate":"2020-06-12","conditions":["Recurrent Malignant Glioma","Brain Glioblastoma"],"enrollment":57,"completionDate":"2025-03-05"},{"nctId":"NCT02259595","phase":"PHASE1","title":"Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC","status":"COMPLETED","sponsor":"Otologic Pharmaceutics, Inc.","startDate":"2014-10","conditions":["Hearing Loss","Sensorineural Hearing Loss","Noise-Induced Hearing Loss"],"enrollment":32,"completionDate":"2015-02"},{"nctId":"NCT00075959","phase":"PHASE2","title":"Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-08","conditions":["Intracerebral Hemorrhage"],"enrollment":600,"completionDate":"2006-01"},{"nctId":"NCT00119626","phase":"PHASE3","title":"Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":["Cerebral Stroke","Ischemic Attack, Transient"],"enrollment":1700,"completionDate":"2005-02"},{"nctId":"NCT00061022","phase":"PHASE3","title":"Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-05","conditions":["Cerebral Stroke","Stroke, Acute","Cerebrovascular Stroke","Ischemic Attack, Transient"],"enrollment":3200,"completionDate":"2006-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"797K01YF1M","CHEBI":"CHEBI:135431","INN_ID":"8187","UMLSCUI":"C2827142","ChEMBL_ID":"CHEMBL1206050","KEGG_DRUG":"D03875","DRUGBANK_ID":"DB17298","PUBCHEM_CID":"6913176","SECONDARY_CAS_RN":"168021-79-2","MESH_SUPPLEMENTAL_RECORD_UI":"C120851"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.6 hours","clearance":"1.35 mL/min/kg","fractionUnbound":"0.6%","volumeOfDistribution":"0.18 L/kg"},"publicationCount":6,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2015 Dec","pmid":"26771008","title":"Noise-Induced Neural Degeneration and Therapeutic Effect of Antioxidant Drugs.","journal":"Journal of audiology & otology"},{"date":"2008 Jan-Feb","pmid":"18389098","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"},{"date":"2007 Jul-Aug","pmid":"17922073","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"},{"date":"2007","pmid":"17658905","title":"Neuroprotective effects of free radical scavengers in stroke.","journal":"Drugs & aging"},{"date":"2006 May","pmid":"16801985","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"DISUFENTON","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Disufenton is a small molecule with the synonyms 2,4-DISULFONYL PNB, CEROVIVE, DISUFENTON DE SODIO, DISUFENTON SODIQUE, DISUFENTON SODIUM, and DISUFENTON SODIUM. It has been studied in clinical trials for various conditions including cerebral stroke, stroke, and recurrent malignant glioma, and has been tested in combination with NXY-059, OKN-007, and Temozolomide (TMZ).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}